MedTrace Logo

Effects of Bidomain Cognitive and Aerobic Training on Cognitive Functioning in Mild Cognitive Impairment.

NCT06867016 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-04-08

No results posted yet for this study

Summary

The study aims to assess the effects of Bidomain cognitive and aerobic training on both cognitive functioning and quality of life in individuals with mild cognitive impairment.

Conditions

Interventions

OTHER

Combined Cognitive & Aerobics Training

The ACT combined training will consist of simultaneous aerobic exercise and cognitive training in a dual-task format, conducted twice a week for 8 weeks. The aerobic training (AT) will consist of twice-weekly sessions that include yoga, brisk walking, pedaling exercises, and step aerobics, alongside cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, 4th week, and 8th week.

OTHER

Cognitive Training

Cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, the 4th week, and the 8th week.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Saliha Ashfaq, MS-NMPT* · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2025-08-28
Completion
2025-08-28

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867016 on ClinicalTrials.gov